• FDA-Approves-Darzalex-Faspro-With-VRd-for-Newly-Diagnosed-Multiple-Myeloma

    Originally published by our sister publication Clinical Oncology NewsBy Clinical Oncology News StaffThe FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech) in combination with VRd (bortezomib, lenalidomide, dexamethasone) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).Efficacy was evaluated in CEPHEUS (ClinicalTrials.gov Identifier: NCT03652064), an open-label, randomized, active-controlled trial in pa

Follow @newsl_pharmacy on Twitter!